US Patent 8043833 Expression of soluble therapeutic proteins
Patent 8043833 was granted and assigned to Novo Nordisk on October, 2011 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+313 characters)
Article
Patent abstract
The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.
Edits on 18 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+6 properties)
Infobox
Patent Inventor Names
Aliakbar Mobasseri0
Bingyuan Wu0
Karl F. Johnson0
Marc F. Schwartz0
Shawn A. DeFrees0
Tarik Soliman0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08043833 Expression of soluble therapeutic proteins US Patent 8043833 Expression of soluble therapeutic proteins
Infobox
Patent Number
080438330
Patent Number
80438330
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
080438330
Date of Patent
October 25, 2011
0Patent Application Number
120921250
Date Filed
September 6, 2006
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08043833 Expression of soluble therapeutic proteins
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08043833
Date of patent
October 25, 2011
Patent application number
12092125
Date Filed
September 6, 2006
Patent primary examiner
Find more entities like US Patent 8043833 Expression of soluble therapeutic proteins
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
